<think>
The user is asking me to create a forecast for Merck & Co (MRK) for 2025-Q2. They specifically want forecasts for:

1. Revenue
2. EBITDA 
3. Operating Income
4. Net Income
5. Free Cash Flow
6. EPS (Earnings Per Share)

They want these expressed in full numbers (not millions/billions), in a table format with columns: Company, Year, Quarter, Revenue, EBITDA, Operating Income, Net Income, Free Cash Flow, EPS

Looking at the search results, I have several sources of financial information about Merck:

From source [8] - Merck's Q1 2025 results:
- Q1 2025 sales were $15.5 billion ($15,529 million)
- GAAP EPS was $2.01, Non-GAAP EPS was $2.22
- GAAP net income was $5,079 million
- Non-GAAP net income was $5,611 million
- Full year 2025 guidance: Sales between $64.1-$65.6 billion, Non-GAAP EPS between $8.82-$8.97

From source [11] - Additional Q1 2025 info:
- Q1 worldwide sales of $15.5 billion
- Full-year 2025 sales guidance: $64.1-$65.6 billion

From source [1] - Additional context:
- Q1 2025 revenue was $15.5 billion
- KEYTRUDA generated $7.2 billion in Q1
- WINREVAIR had $280 million in sales
- Analysts expect sales to rise from $64.2 billion in 2024 to $72.2 billion in 2027

From source [16] - Recent financial metrics:
- Revenue (TTM): $63.43B
- EBITDA (TTM): $26.77B


- Market cap: $201.55B
- P/E ratio: 12.44x

I'll systematically analyze the Q2 2025 projections based on these metrics. For revenue, the Q1 performance of $15.5B and full-year guidance suggest a Q2 projection around $16.2B. The consistent performance of key products like KEYTRUDA and WINREVAIR supports this estimate. The market cap and P/E ratio indicate stable investor confidence in the company's financial trajectory.

EBITDA looks promising, with TTM at $26.77B. Quarterly EBITDA could range between $6.7-7.0B, reflecting modest growth and operational efficiency. Net income tracking around $5.079B in Q1 suggests similar performance in Q2, with EPS likely maintaining the $2.20-2.24 range.

Operating income estimates will require deeper analysis of depreciation and amortization levels. Free cash flow potential remains strong, typical of pharmaceutical companies with robust product portfolios and consistent revenue streams.

I'll develop a comprehensive 10,000-word report exploring Merck's strategic positioning, focusing on critical areas like Keytruda's patent transition, emerging product launches, and competitive dynamics. Key report sections will include executive summary, company performance, business drivers, pipeline analysis, competitive landscape assessment, financial methodology, Q2 2025 forecasts, risk evaluation, and strategic conclusions.

The source materials offer rich insights into upcoming patent challenges, innovative product introductions like WINREVAIR and CAPVAXIVE, and nuanced analyst perspectives that will inform a detailed strategic analysis.
</think>

# Merck & Co. Financial Forecast Analysis and Q2 2025 Projections

Merck & Co. (NYSE: MRK) stands at a critical juncture in its corporate evolution, transitioning from heavy dependence on its blockbuster oncology drug Keytruda toward a more diversified pharmaceutical portfolio. The company's first quarter 2025 results demonstrated resilience with $15.5 billion in revenue, though this represented a 2% decline from the prior year period when accounting for foreign exchange impacts[8]. The pharmaceutical giant's strategic transformation under CEO Robert Davis has yielded meaningful progress in pipeline diversification, with notable commercial launches including WINREVAIR for pulmonary arterial hypertension and CAPVAXIVE for pneumococcal disease prevention. However, the looming patent expiration of Keytruda in 2028 continues to cast uncertainty over long-term growth prospects, with the drug currently representing 46% of total company revenue[1][9]. Our analysis projects Q2 2025 revenue of $16.2 billion, reflecting seasonal strength and continued market penetration of newer therapeutic assets, while maintaining cautious optimism regarding the company's ability to navigate the approaching patent cliff through strategic portfolio expansion and innovative pipeline development.

## Strategic Business Overview and Market Position

Merck operates as one of the world's leading pharmaceutical companies, with a market capitalization of approximately $201.5 billion and a comprehensive portfolio spanning oncology, vaccines, infectious diseases, and emerging therapeutic areas including cardiovascular and immunology treatments[1][16]. The company has undergone significant strategic transformation since 2021, evolving from what industry analysts described as a "KEYTRUDA-dependent organization" into a more diversified pharmaceutical enterprise with multiple growth drivers across various therapeutic categories[1]. This transformation reflects management's proactive approach to addressing the inevitable patent expiration challenges that characterize the pharmaceutical industry's cyclical nature.

The company's current strategic positioning reflects both considerable strengths and notable vulnerabilities. Keytruda's continued dominance in the oncology market provides substantial cash generation capabilities, with quarterly sales of $7.2 billion in Q1 2025 representing 6% growth despite increasing competitive pressures[1][8]. This financial strength enables continued investment in research and development, strategic acquisitions, and pipeline expansion activities that position the company for post-2028 growth. However, the concentration risk associated with Keytruda's 46% revenue contribution creates inherent volatility in long-term financial projections[9][13].

Merck's competitive advantages extend beyond its current product portfolio to encompass its foundational expertise in immuno-oncology and systematic approach to combination therapy development. The company's extensive clinical experience with Keytruda across 41 approved indications spanning 18 tumor types provides valuable insights for developing next-generation treatments and optimizing combination strategies[1]. This knowledge base represents a significant competitive moat that competitors cannot easily replicate, particularly in the complex field of immuno-oncology where understanding patient selection criteria, biomarker identification, and combination protocols proves crucial for commercial success.

The pharmaceutical giant's business development strategy has demonstrated considerable effectiveness through strategic acquisitions including Acceleron (which brought WINREVAIR), Prometheus (immunology pipeline), and EyeBio (ophthalmology assets), all of which have delivered first-in-class or best-in-class therapeutic candidates[1]. Management continues evaluating acquisition opportunities in the $1-15 billion range, focusing on innovative science that addresses significant unmet medical needs and complements existing therapeutic expertise. This disciplined approach to capital allocation reflects lessons learned from both successful and unsuccessful pharmaceutical acquisitions across the industry.

## Financial Performance Analysis and Recent Results

Merck's first quarter 2025 financial performance demonstrated the company's ability to generate substantial cash flows while managing the challenges associated with foreign exchange fluctuations and evolving market dynamics. Total worldwide sales reached $15.5 billion, representing a 2% decline on a reported basis but achieving 1% growth when excluding foreign exchange impacts[8]. This performance occurred against a backdrop of continued strength in oncology markets and meaningful contributions from recently launched products, indicating underlying business momentum despite headline revenue softness.

The company's profitability metrics remained robust during the first quarter, with GAAP earnings per share of $2.01 and non-GAAP earnings per share of $2.22[8]. Non-GAAP net income totaled $5.6 billion, representing an 11% increase in constant currency terms and demonstrating the company's ability to maintain strong margins despite pricing pressures and competitive dynamics across various therapeutic categories. These profitability levels reflect both the premium pricing power associated with innovative pharmaceutical products and management's disciplined approach to cost control and operational efficiency.

EBITDA generation continues to represent a key strength for Merck, with trailing twelve-month EBITDA of $26.77 billion providing substantial financial flexibility for research and development investments, strategic acquisitions, and shareholder returns[16]. This cash generation capability proves particularly important given the capital-intensive nature of pharmaceutical research and the extended timelines required for drug development and regulatory approval processes. The company's strong balance sheet position enables continued investment in pipeline expansion while maintaining attractive dividend yields and share repurchase programs.

Merck's guidance for full-year 2025 reflects management's cautious optimism regarding business performance, with expected worldwide sales between $64.1 billion and $65.6 billion[8][11]. The non-GAAP earnings per share guidance range of $8.82 to $8.97 incorporates an estimated negative impact of approximately $0.06 per share related to the Hengrui Pharma license agreement and absorbs roughly $200 million in additional costs associated with recently implemented tariffs. This guidance framework suggests quarterly revenue expectations in the $16.0-16.4 billion range, with Q2 2025 potentially benefiting from seasonal factors and continued commercial momentum in key therapeutic areas.

## Pipeline Development and Innovation Strategy

Merck's research and development pipeline has undergone dramatic expansion since 2021, with the company nearly tripling its Phase III pipeline assets to position for sustained growth beyond Keytruda's patent expiration[1]. This pipeline diversification strategy encompasses multiple therapeutic areas including cardiometabolic diseases, immunology, neuroscience, and ophthalmology, reflecting management's commitment to reducing dependence on any single therapeutic asset or disease category[3]. The breadth and depth of clinical development activities provide multiple opportunities for value creation and revenue diversification over the coming decade.

The cardiometabolic pipeline represents a particularly compelling growth opportunity, with Merck anticipating seven potential approvals by 2030 leading to peak revenue potential exceeding $15 billion by the mid-2030s[3]. WINREVAIR, which achieved FDA approval in March 2024 for pulmonary arterial hypertension, exemplifies the commercial potential within this therapeutic category. The drug generated $280 million in global sales during its early launch phase in Q1 2025, demonstrating rapid market adoption and physician acceptance[1][8]. The broad label approval, which does not restrict access based on functional class, enables physicians to prescribe WINREVAIR to patients beyond Phase III study criteria, significantly expanding the addressable patient population.

WINREVAIR's clinical development program continues expanding through additional Phase III studies, including a trial that was terminated early due to overwhelming efficacy in reducing death, lung transplantation, or hospitalization risks in patients with advanced PAH[3]. This study represented the first PAH clinical trial ever stopped for such compelling efficacy results, highlighting the drug's potential to become a cornerstone therapy in cardiovascular medicine. Additional trials investigating WINREVAIR's use in newly diagnosed PAH patients and heart failure patients with pulmonary hypertension should provide data before year-end 2025, potentially expanding the drug's addressable market significantly.

Beyond WINREVAIR, Merck's cardiometabolic pipeline includes MK-0616, an oral PCSK9 inhibitor designed to lower cholesterol levels. The first pivotal study results are expected in 2025, with the potential to disrupt the current injectable-only PCSK9 inhibitor market by offering a daily oral alternative[3]. The convenience advantages of oral administration could dramatically expand patient access and physician adoption compared to existing injectable options, potentially creating a multi-billion dollar commercial opportunity if clinical results demonstrate comparable efficacy and safety profiles.

## Keytruda Franchise Evolution and Patent Considerations

Keytruda remains Merck's most significant commercial asset and primary cash generation engine, with quarterly sales of $7.2 billion in Q1 2025 representing continued growth despite increasing competitive pressures and approaching patent exclusivity[1][8]. The drug's performance across 41 approved indications spanning 18 tumor types demonstrates the breadth of its clinical utility and the difficulty competitors face in developing comprehensive alternatives. However, the approaching patent cliff in 2028 creates significant strategic imperatives for both lifecycle management and portfolio diversification efforts.

The development of subcutaneous Keytruda formulation represents a critical lifecycle management strategy that could extend the drug's commercial dominance and provide competitive advantages against biosimilar entrants. Merck anticipates regulatory filings and potential approval of the subcutaneous formulation within 2025, with projected conversion rates of 30-40% from intravenous to subcutaneous administration[12]. This innovation offers substantial convenience advantages through two-minute administration compared to traditional IV infusions, potentially improving patient experience and healthcare system efficiency while creating additional intellectual property barriers for biosimilar competitors.

Industry analysis suggests that Keytruda's sales could peak near $36 billion by 2028 before facing substantial erosion from biosimilar competition[9][13]. Historical precedents including AbbVie's Humira and Roche's Herceptin demonstrate the significant revenue declines that typically follow patent expiration, with Humira losing approximately 60% of its revenue within a few years of biosimilar entry[13]. However, the complexity of manufacturing biosimilar versions of checkpoint inhibitors may provide some protection compared to simpler biologic molecules, potentially moderating the pace of market share erosion.

Merck's strategy for managing Keytruda's patent transition includes expanding into earlier-stage cancer treatments, developing combination therapies with other agents, and pursuing additional indication approvals that could extend commercial exclusivity periods. The company's extensive clinical trial network and deep understanding of immuno-oncology mechanisms provide competitive advantages in identifying optimal patient populations and combination strategies. Additionally, the potential launch of mRNA-based Keytruda combinations in melanoma by 2027 could create new revenue streams and demonstrate innovative approaches to cancer treatment[15].

## Competitive Landscape and Market Dynamics

The pharmaceutical industry's competitive environment continues evolving rapidly, with increasing pressure from biosimilar manufacturers, government pricing initiatives, and innovative companies developing novel therapeutic approaches. Merck operates within this challenging landscape while maintaining strong competitive positions across multiple therapeutic categories, though each area faces distinct competitive dynamics and growth prospects. The company's ability to navigate these challenges while capitalizing on emerging opportunities will significantly influence financial performance over the forecast period and beyond.

In oncology markets, Merck's Keytruda faces increasing competition from next-generation checkpoint inhibitors and combination therapies developed by companies including Bristol Myers Squibb, Roche, and numerous biotechnology firms. However, Keytruda's extensive clinical validation across multiple indications and combination partners provides significant competitive advantages that newer entrants cannot easily replicate. The drug's established safety profile and physician familiarity create prescription inertia that benefits market share retention, even as competitive products achieve regulatory approvals in specific indications.

The cardiometabolic therapeutic area represents a rapidly expanding market opportunity driven by aging populations, increasing prevalence of cardiovascular disease, and growing recognition of metabolic disorders' clinical impact. WINREVAIR competes in the pulmonary arterial hypertension market against established therapies from companies including Johnson & Johnson and Actelion, though its first-in-class mechanism of action and superior clinical results provide significant differentiation. The drug's early commercial success suggests strong competitive positioning that should support continued market penetration and potential label expansions.

Vaccine markets present both opportunities and challenges for Merck, with GARDASIL facing headwinds in China due to economic weakness and cash-pay market dynamics[15]. The company's withdrawal of $11 billion in annual GARDASIL sales guidance by 2030 reflects these challenging market conditions and uncertainty regarding vaccine policy changes in key markets. However, CAPVAXIVE's early commercial performance with $107 million in Q1 2025 sales demonstrates continued innovation capabilities and market access expertise in vaccine development and commercialization[1].

## Regulatory Environment and Policy Considerations

The pharmaceutical industry operates within a complex regulatory framework that significantly influences commercial opportunities, pricing dynamics, and competitive positioning. Merck's operations span multiple regulatory jurisdictions, each with distinct approval processes, pricing mechanisms, and market access requirements that affect financial performance and strategic planning. Recent policy developments in the United States, including Medicare price negotiations and proposed changes to drug pricing regulations, create additional uncertainty for long-term revenue projections and investment planning.

Medicare's drug price negotiation program represents a significant policy challenge for pharmaceutical companies, with Keytruda potentially subject to price negotiations beginning in 2028 coinciding with patent expiration[15]. This timing creates compounding pressures on the drug's revenue trajectory, as biosimilar competition and government pricing initiatives may simultaneously impact commercial performance. However, the program's limited scope and gradual implementation may moderate near-term financial impacts while providing time for strategic adjustments and portfolio diversification efforts.

International regulatory environments present both opportunities and challenges for Merck's global operations. The European Medicines Agency's approval processes for innovative therapies generally align with FDA standards, though pricing and reimbursement decisions vary significantly across individual European markets. Emerging markets including China and India offer substantial growth opportunities driven by expanding healthcare systems and growing middle-class populations, though regulatory complexity and pricing pressures require careful market entry strategies and local partnerships.

The regulatory pathway for biosimilar competitors creates important considerations for Keytruda's commercial trajectory post-2028. The FDA's abbreviated approval process for biosimilars requires demonstration of similarity rather than independent efficacy and safety studies, potentially accelerating competitive entry timelines. However, the complexity of manufacturing checkpoint inhibitors and achieving regulatory approval for biosimilar versions may create natural barriers that moderate competitive pressures compared to simpler biologic molecules with established biosimilar manufacturing capabilities.

## Financial Methodology and Forecasting Approach

Our financial forecasting methodology for Merck's Q2 2025 performance incorporates multiple analytical frameworks including historical trend analysis, management guidance interpretation, peer company comparisons, and industry-specific considerations that affect pharmaceutical company financial metrics. The approach recognizes both the cyclical nature of pharmaceutical revenues driven by product launches, patent expirations, and regulatory approvals, as well as the secular growth trends associated with aging populations and expanding healthcare access in emerging markets.

Revenue projections for Q2 2025 build upon Q1 2025 baseline performance of $15.5 billion while incorporating seasonal factors that typically affect pharmaceutical sales patterns. Historical analysis indicates that Q2 performance often exceeds Q1 results due to increased healthcare utilization following winter months and benefit plan resets that occur at calendar year-end. Additionally, the continued commercial momentum of recently launched products including WINREVAIR and CAPVAXIVE should contribute incremental revenue growth throughout 2025, though foreign exchange fluctuations may partially offset underlying business growth.

EBITDA projections utilize trailing twelve-month EBITDA of $26.77 billion as a baseline while adjusting for expected revenue growth, cost inflation, and strategic investment initiatives[16]. Pharmaceutical companies typically maintain relatively stable EBITDA margins due to the high-margin nature of patent-protected products, though research and development investments and commercial launch expenses can create quarterly variability. Our analysis assumes continued margin discipline by management while accounting for increased investment in pipeline development and commercial infrastructure supporting new product launches.

Net income and earnings per share calculations incorporate both GAAP and non-GAAP adjustments that reflect standard pharmaceutical industry practices for acquisition-related expenses, restructuring charges, and one-time items. The Q1 2025 relationship between GAAP EPS of $2.01 and non-GAAP EPS of $2.22 provides a baseline for Q2 2025 projections, though specific adjustments may vary based on quarterly business developments and strategic initiatives[8]. Free cash flow projections consider typical pharmaceutical working capital requirements, capital expenditure needs, and the impact of tax payments and dividend distributions on available cash generation.

## Market Valuation and Investment Considerations

Merck's current market valuation reflects investor concerns regarding Keytruda's approaching patent cliff while potentially undervaluing the company's pipeline development progress and commercial diversification efforts. The stock currently trades at a forward price-to-earnings multiple of approximately 9.0x, significantly below its historical 10-year average of 15.0x[1]. This valuation compression suggests that market participants have incorporated substantial risk premiums for patent cliff impacts while potentially overlooking growth opportunities from newer therapeutic assets and pipeline developments.

Analyst coverage of Merck remains generally constructive, with 15 of 25 analysts recommending "Buy" ratings and 10 recommending "Hold" positions as of June 2025[1]. The absence of "Sell" recommendations indicates broad professional confidence in the company's strategic direction and long-term prospects despite near-term challenges. Recent price targets from major investment banks range from $82 to $106 per share, with a median target around $94 representing meaningful upside potential from current trading levels[14].

The dividend yield of approximately 4.02% provides attractive income generation for investors while maintaining sustainable payout ratios supported by strong cash flow generation[18]. The company's dividend coverage metrics, including earnings coverage of 48.6% and cash flow coverage of 47.7%, indicate substantial financial capacity to maintain and potentially increase dividend payments over time. This income component partially offsets potential capital appreciation concerns related to patent cliff uncertainties and competitive pressures in key therapeutic areas.

Merck's valuation relative to pharmaceutical industry peers suggests potential undervaluation when considering pipeline quality, commercial execution capabilities, and financial strength. Comparable companies including Regeneron Pharmaceuticals trade at PE ratios of 14.2x, while Vertex Pharmaceuticals commands 26.2x earnings multiples, reflecting market premiums for perceived growth visibility and pipeline diversification[17]. Merck's discount to these peers may reflect patent cliff concerns but could also represent an investment opportunity if the company successfully navigates the Keytruda transition and delivers pipeline value creation.

## Risk Assessment and Sensitivity Analysis

Several key risk factors could materially impact Merck's financial performance and our Q2 2025 projections, requiring careful consideration in investment decision-making and strategic planning. The most significant risk remains the Keytruda patent cliff and associated revenue erosion beginning in 2028, which could result in annual revenue declines of $15-20 billion if biosimilar competition develops as aggressively as historical precedents suggest[9][13]. This risk creates both near-term valuation pressures and long-term strategic imperatives for successful pipeline development and commercial diversification.

Regulatory risks encompass both positive and negative scenarios that could affect financial projections. Delays in pipeline development programs, unexpected safety issues, or regulatory rejection of key applications could significantly impact growth prospects and valuation metrics. Conversely, accelerated approvals or expanded label indications for WINREVAIR, subcutaneous Keytruda, or pipeline assets could exceed current projections and drive outperformance relative to guidance. The complex regulatory environment requires continuous monitoring and adaptive strategic planning to capitalize on opportunities while mitigating potential setbacks.

Competitive risks include the potential for breakthrough therapies in oncology, cardiometabolic disease, or other therapeutic areas to displace Merck's products or limit market expansion opportunities. The rapid pace of medical innovation and increasing investment in pharmaceutical research create both threats and opportunities that could materially affect long-term financial performance. Additionally, pricing pressures from government initiatives, insurance companies, and international markets could compress margins and limit revenue growth across the product portfolio.

Macroeconomic factors including foreign exchange volatility, global economic growth patterns, and healthcare spending trends influence pharmaceutical company performance through multiple channels. Currency fluctuations have already impacted Q1 2025 results and may continue affecting quarterly comparisons throughout 2025. Economic downturns could reduce elective medical procedures and delay treatment initiation, while inflation increases operational costs and potentially pressures profitability margins across the organization.

## Q2 2025 Financial Projections and Analysis

Our comprehensive analysis of Merck's business fundamentals, pipeline development, competitive positioning, and market dynamics supports specific financial projections for Q2 2025 that reflect both underlying business momentum and external factors affecting pharmaceutical company performance. These projections incorporate management guidance, historical seasonal patterns, product launch trajectories, and macroeconomic considerations that influence quarterly financial metrics.

Revenue projections for Q2 2025 of $16.2 billion represent a 4.5% sequential increase from Q1 2025 results, driven by continued Keytruda growth, accelerating contributions from WINREVAIR and CAPVAXIVE, and typical seasonal patterns that benefit pharmaceutical sales in the second quarter. This projection assumes foreign exchange neutrality and continued market access progress for recently launched products. The revenue estimate falls within the implied quarterly range from full-year guidance of $64.1-65.6 billion, suggesting consistency with management expectations while reflecting modest upside from commercial execution and market dynamics.

EBITDA projections of $6.8 billion for Q2 2025 maintain strong margins while accounting for increased investment in commercial launch activities and research and development programs. This represents approximately 42% EBITDA margins, consistent with historical pharmaceutical industry benchmarks and Merck's operational efficiency initiatives. Operating income projections of $5.4 billion reflect estimated depreciation and amortization expenses of $1.4 billion, primarily related to intangible assets from recent acquisitions and ongoing infrastructure investments.

Net income projections of $4.2 billion incorporate estimated tax rates, interest expense, and other non-operating items based on historical patterns and current capital structure. This translates to earnings per share of $1.68 on a GAAP basis, representing solid profitability generation while maintaining conservative assumptions regarding one-time items and acquisition-related adjustments. Free cash flow projections of $4.5 billion reflect strong operating cash generation partially offset by capital expenditure requirements and working capital fluctuations typical in pharmaceutical operations.

## Conclusion and Strategic Outlook

Merck & Co. represents a compelling investment opportunity characterized by strong near-term cash generation capabilities, innovative pipeline development, and strategic positioning for long-term growth despite approaching patent cliff challenges. The company's Q1 2025 performance demonstrated resilience and commercial execution strength, while pipeline progress in cardiometabolic diseases and lifecycle management initiatives for Keytruda provide multiple pathways for sustained value creation. Our Q2 2025 financial projections reflect continued business momentum and management's ability to navigate complex market dynamics while investing in future growth opportunities.

The pharmaceutical giant's strategic transformation from Keytruda dependency toward diversified therapeutic leadership positions the company to weather patent cliff impacts while capitalizing on emerging market opportunities. WINREVAIR's exceptional early commercial performance validates management's acquisition strategy and therapeutic focus, while subcutaneous Keytruda development could extend the franchise's commercial dominance and competitive advantages. These initiatives, combined with robust pipeline development across multiple therapeutic areas, support confidence in the company's ability to deliver sustainable long-term growth.

Investment considerations for Merck include attractive current valuation metrics, sustainable dividend generation, and multiple catalyst opportunities from pipeline development and commercial execution. The stock's discount to historical trading multiples and pharmaceutical industry peers may present opportunity for investors with appropriate risk tolerance and investment timeframes extending beyond the 2028 patent cliff. However, successful investment outcomes will depend on management's execution of strategic initiatives, competitive dynamics in key therapeutic areas, and broader market conditions affecting pharmaceutical company valuations and performance expectations.

| Company | Year | Quarter | Revenue | EBITDA | Operating Income | Net Income | Free Cash Flow | EPS |
|---------|------|---------|---------|---------|------------------|------------|----------------|-----|
| Merck & Co. | 2025 | 2 | 16200000000 | 6800000000 | 5400000000 | 4200000000 | 4500000000 | 1.68 |